Customer support

xie@china-sinoway.com
EnglishEnglish
banner
Products
Home

API

Vildagliptin 274901-16-5

Vildagliptin 274901-16-5

99% up by HPLC
  • Product Details

Product Information


Product name

Vildagliptin

CAS No.

274901-16-5

Molecular Formula

C17H25N3O2

Molecular Weight

303.404

Quality Standard

99% up by HPLC

Appearance

White or whitish solid powder


COA of Vildagliptin


ITEMS

SPECIFICATION

RESULT

Appearance

White or whitish solid powder

White solid powder

Identity

High-performance liquid chromatograph HPLC:

The retention time of test sample major peak complies to reference standard

Almost the same

IR Infrared spectrometry:

The IR spectrum of test sample should comply to reference standard

Almost the same

Melting point

148.0 C - 152.0C

148.6.0C-149.1C

Loss on drying

1.0%

0.36%

Residual on ignition

0.1%

0.04%

Related substance

Any single impurity 0.1%

Total impurities 1.0%

Conforms

0.65%

Heavy metals

20 ppm

< 10 ppm

Assay

99.0% - 102.0%

99.19%

Conclusion

The sample complies with the above specification


Usage


Vildagliptin is a selective, competitive and reversible DPP24 inhibitor. Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like polypeptide 1 (GLP-1) are important hormones to maintain glucose concentration in the body, and both have incretin effects. The insulin-stimulating effect of GIP in patients with type 2 diabetes is impaired, and only GLP-1 can play the role of insulin-stimulating hormone secretion. GLP-1 also inhibits glucagon secretion and suppresses gastric emptying to increase satiety (suppression of appetite). DPP24 binds to proteins and exists in many tissues, such as kidney, liver, brush border of small intestinal membrane, pancreatic duct, lymphocytes, endothelial cells, and it can rapidly degrade GLP-1 by hydrolyzing the N-terminal 2 alanine of GLP-1. inactivated. This product inhibits the activity of this enzyme by combining with DPP24 to form a DPP24 complex. It increases the concentration of GLP-1 and promotes the production of insulin by islet β cells, while reducing the concentration of glucagon, thereby reducing blood sugar. and had no significant effect on body weight.


Vildagliptin can reduce fasting and postprandial blood glucose levels, postprandial glucagon secretion and improve B cell function, providing a new option for the treatment of type 2 diabetes patients. Safety and effectiveness of this medicine in combination with other medicines.


*Products under the patent are only for R&D use

Send A Message

If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.
Related Products

Spironolactone
Spironolactone 52-01-7
EP8, USP38,99.95% up by HPLC, total impurities < 0.05%
Mupirocin powder
Mupirocin 12650-69-0
99% up by HPLC / GMP
Imatinib mesylate
Imatinib Mesylate 220127-57-1
In-house Standard
Ceftiofur sodium
Ceftiofur sodium 104010-37-9
In-house Specification
Thymopentin
Thymopentin 69558-55-0
99% up Medical Grade
Azilsartan
Azilsartan 147403-03-0
99% up, JP/ GMP / PMDA / DMF
Send A Message
Send A Message
If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.

Home

Products

about

Contact